

Cloning and Expression of *B. melitensis* bp26 Gene in *Lactococcus lactis* as a Food Grade VaccineMaryam Azizpour Maghvan¹, Parvaneh Jafari¹, Seyed Davood Hoseini^{2*},
and Ali mohammad Behrozkah³¹. Department of Microbiology, Islamic Azad University, Arak Branch, Arak, Iran². Razi Vaccine and Serum Research Institute, Agricultural Research, Education & Extension Organization, Arak, Iran³. Razi Vaccine and Serum Research Institute, Agricultural Research, Education & Extension Organization, Karaj, Iran

Abstract

Background: Brucellosis is still an important health problem in under developing countries and researches for finding efficient vaccine are going on. *Brucella melitensis* (*B. melitensis*) bp26 gene is a good candidate for brucellosis vaccine and investigations showed that *Lactococcus lactis* (*L. lactis*) with several positive characteristic are attractive for protein expression as a live delivery vectors. These fast growing bacteria need no aeration, are easy to handle, have no exotoxin, endotoxin and protease, so the cost of culturing is inexpensive.

Methods: *B. melitensis* bp26 gene was cloned in food grade pNZ 8149 vector and expressed in *L. lactis* NZ 3900.

Results: Results showed that we can produce a food-grade recombinant *L. lactis* producing the *B. melitensis* BP26 protein.

Conclusion: In this study, for Future evaluation about ability of *L. lactis* as a live delivery vector, a food-grade recombinant *L. lactis* producing the *B. melitensis* BP26 protein was produced.

Avicenna J Med Biotech 2019; 11(3): 264-267

Keywords: Brucellosis, Exotoxins, *Lactococcus lactis*, Vaccines

Introduction

Brucellosis is zoonotic diseases which made health and economic problem in many countries¹. In industrialized nations because of routine screening of domestic livestock and animal vaccination brucellosis in humans and livestock are relatively uncommon. Up to now no human vaccines are available, and current animal vaccines are both virulent in humans and lack clinical efficacy². Therefore, an efficient, economical and easily managed vaccine needs to be developed.

Researchers revealed that *Brucella melitensis* (*B. melitensis*) bp26 gene is a good immunogen and can be candidate for *Brucella* spp vaccine³. This gene encoding the 28 kDa periplasmic protein is named BP26, CP28 or Omp28 and is a target molecule to detect anti-*Brucella* antibodies^{4,5}. To date, *Lactococcus lactis* (*L. lactis*) is attractive live delivery vector through mucosal routes for delivering bioactive proteins. *L. lactis* enters through M cells and multiplied within phagocytic cells so releasing and spreading in deeper layer was occurred. Therefore induction of immune responses against *L. lactis* antigens was Getting Started⁶⁻¹⁰. PNZ8149 was used as the broad host range vector. This vector produces a cytoplasmic protein and to prevent

protein removal by digestive enzymes or by other factors in the digestive tract, this protein was not designed to be secreted or attached to the cell surface of bacteria. Therefore, after entering of this recombinant bacterium through the M cells and up taking via phagocytic cells, the probability of induction the immune system, through BP26 protein, is higher¹⁰.

In this study for first time, *B. melitensis* bp26 gene was cloned into the PNZ 8149 vector and expressed in *L. lactis* NZ 3900 for used as a research experimental tool to find a good vaccine candidate.

Materials and Methods

Bacterial strains and growth conditions

Any bacterial strains and plasmids used in this study are showed in table 1. All *L. lactis* strains were grown at 30 °C on M17 media (Merck, Germany) containing 0.5% glucose (M17-glu) or lactose (M17-lac). All *Escherichia coli* (*E. coli*) DH5a strain were grown at 37 °C on Luria-Bertani (LB) medium (Merck, Germany) containing 50 µg/ml Ampicillin or 50 µg/ml kanamycin.

* Corresponding author:
Seyed Davood Hoseini, Ph.D.,
Razi Vaccine and Serum
Research Institute, Arak, Iran
Tel: +98 86 33544702
Fax: +98 86 33544704
E-mail:
hosseinida@yahoo.com
Received: 13 Jan 2018
Accepted: 8 Apr 2018

Table 1. Bacteria strains and plasmids used in this study

Strains or plasmids	Relevant characteristics	Source
Strains		
<i>E. coli</i> DH5 α	Host	Fermentas Kit
<i>L. lactis</i> NZ39000	Host	Mo Bi Tec Co
<i>L. lactis</i> NZ8149	harboring pNZ8149 plasmid	Mo Bi Tec Co
<i>E. coli</i> DH5 α	harboring recombinant pET28a +bp26 plasmid	Our lab preserved (3)
Plasmids		
pTZ57R/T	<i>E. coli</i> TA cloning vector	Fermentas Kit
pNZ8149	Food grade <i>L. lactis</i> lacF selection marker,	Mo Bi Tec Co

Amplification of bp26 gene

To amplify the *bp26* gene, one pair of PCR primers was designed based on sequences published in Gene Bank (accession No. JF918758.1), and the restriction endonuclease sites of XbaI and SphI were added to both ends of the modified *bp26* protein gene e based on the structure of PNZ8149 (forward: GCATGCATGA ACACTCGTGC and reverse: TCTAGATTACTTGAT TTCAAAAACGAC). Template DNA (pET28a+bp26) preserved by Our lab³. The PCR was performed initial denaturation at 95 °C for 2 min, followed by 34 cycles of 95 °C for 1 min, 58 °C for 1 min, and 72 °C for 1 min. with Extra polymerization in 72 °C for 30 min. The PCR product consisting 753 bp was checked using agarose gel electrophoresis and then purified using a Fermentas Silica Bead DNA Gel Extraction Kit.

Cloning and transformation

The PCR product was cloned in to pTZ57R/T vector and transformed in *E. coli* DH5 α competent cells. The recombinant pTZ57R/T plasmid was extracted and digested with two restriction enzymes (SphI /NEB Bio lab and XbaI/Fermentas Digestion Enzyme). At the same time the pNZ8149 plasmid was digested with both SphI and XbaI and purified. The purified desire was inserted into the pNZ8149. Competent *L. lactis* NZ39000 cells were then electro-transformed with the recombinant plasmids (Gene e-Pulser; Bio-Rad, Hercules, CA, USA) and cultured on Elliker agar-lac bromocresol purple and incubated at 30 °C for 48 hr. Transformants harboring the recombinant plasmids were verified through enzymatic digestion and PCR.

Expression of recombinant protein

Expression performed according to MoBiTec NICE_Expression_System and analyzed on 10% SDS- PAGE. To confirm the accuracy of the SDS-Page and protein expression, Western Blot was performed with Nitrocellulose Membrane (Sigma) and using the Trans-Blot SD cell (BIO-RAD). After blocking with TBST (tris-buffered saline, 0.05% Tween-20) buffer containing 5% skimmed milk at 4 °C overnight, the membranes were incubated with a mouse IgG monoclonal antibody, anti- OMP28, (MyBioSource, Inc, USA) at a dilution 1:500 in phosphate-buffered saline (PBS) at a 37 °C for 60 min. Then, the blots were washed and incubated with 1:2000 dilution of HRP-conjugated rabbit anti-




Figure 1. Colony PCR from random selected colonies on 1% agarose gel: Lane 1; Fermentas 1 Kb DNA Ladder, Lane 3, 4, 5, 6 and 7; negative colonies, Lane 2; positive colonies.

mouse IgG (MyBioSource, Inc, USA) for 60 min. Binding was visualized using diaminobenzidine (Merck), according to the manufacturer's instruction.

Results

PCR screening

Results showed that the expected DNA band of the *bp26* gene had been amplified; the PCR product was approximately 753 bp in length plus the 12 bp restriction sites (Figure 1).

Digestion screening

Double-digestion confirms the size of *bp26* gene (Figure 2).

Induced expression of the recombinant *L. lactis*

Results of *bp26* gene expression on SDS-PAGE; as it is evident in the figure, with increasing Nisin (1 ng/ml) addition time, the amount of protein expression also increases. Protein production increase with Nisin and in 5th hr the high level of protein production was seen. Results indicated that the molecular weight of the expressed recombinant protein was approximately 28 kDa (Figure 3).

Western blot results showed that the produced protein was the *B. melitensis* omp28 (Figure 4). The result show that the binding of BP26 protein and its antibody occurred.




Figure 2. Double-digestion on 1% agarose gel: Lane 1; pNZ 8149, Lane 2; Fermentas 1 Kb DNA Ladder, Lane 3; pNZ 8149+ bp26 double-digestion.




Figure 3. *bp26* gene expression on SDS-PAGE: Lane 1; *L. lactis* with pNZ 8149 vector, Lane 2; *L. lactis* 3900, Lane 3; Fermentas protein Ladder, Lane 4; transformed *L. lactis* with recombinant pNZ 8149+bp26 vector before adding Nisin, Lane 5; transformed *L. lactis* with recombinant pNZ 8149+bp26 vector 1 hr after adding Nisin, Lane 6; transformed *L. lactis* with recombinant pNZ 8149+bp26 vector 3 hr after adding Nisin, Lane 7; transformed *L. lactis* with recombinant pNZ 8149+bp26 vector 5 hr after adding Nisin.




Figure 4. BP26 production was approved by western blot analysis. Lane 1; BP26 before adding nisin, Lane 2; BP26 production 1 hr after adding nisin, Lane 3; BP26 production 3 hr after adding nisin, Lane 4; BP26 production 5 hr after adding nisin.

Discussion

Brucellosis is a worldwide zoonotic disease, which remain an important public health concern and causes economic losses in endemic areas^{11,12}. Vaccination is the most possible way to reduce the transmission in domestic animal herds and humans. The infectious cycles of most pathogenic micro-organisms initiate from mucosal surfaces. So, if colonization and invasion of infectious agents stopped in this stage, the infection does not happen. For this purpose, a vaccine must be

made to stimulate mucosal and cellular immunity¹³⁻¹⁵. Today, investigations showed that using Lactic Acid Bacteria (LAB) as a live delivery vectors for antigens can induce mucosal immunity and one of the most important candidates to produce mucosal vaccines. In this investigation, we used *L. lactis* 3900 as a gene delivery vehicle. Despite the fact that *L. lactis* is a non-commensal and non-colonizing bacterium at the level of the gastrointestinal tract, it can be easily taken up by M cells, and exhibits adjuvant/immune potentiating activity^{16,17}. As *Brucella* infections involve mainly bacterial entry through the mucosal routes, the development of successful approaches for oral vaccination could radically alter the current scene of brucellosis^{18,19}. Most published studies have evaluated the use of live vectors expressing *Brucella* antigens for vaccine delivery at the mucosal gut. At present, several recombinant proteins of *Brucella* have been evaluated as oral vaccine with *L. lactis* and sufficient evidence showed that they can induce protective immunity in mice¹⁹⁻²³. For example, in 2002, Luciana A. Ribeiro *et al* expressed *Brucella abortus* L7/L12 gene in *L. lactis*, under the nisin-inducible promoter²². In another work, Daniela S. Pontes *et al* in 2003, revealed that a recombinant *Lactococcus lactis* strain producing L7/L12 under the control of nisin inducible promoter when orally administered to BALB/c mice, they could induced local humoral immune response and detected significant levels of anti-L7/L12 specific IgA in feces²¹.

In 2012 DarwinSáez *et al*, transformed *Brucella abortus* (*B. abortus*) Cu-Zn Superoxide dismutase (SOD) in *L. lactis* revealed that orally vaccinated mice protected against challenge with the virulent *B. abortus* 2308 strain¹⁹.

Conclusion

According to the investigations which mentioned above and considering that *B. melitensis* BP26 is a good immunogenic protein²⁴, in this study, we successfully constructed a food-grade recombinant *L. lactis* producing the *B. melitensis* BP26 protein for future researches about induction of immune response by this protein.

Acknowledgement

The authors thank Dr. Behrozikhah, Razi Vaccine and Serum Research Institute, Agricultural Research, Education & Extension Organization, Karaj, Iran and Dr. Tavangar, Razi Vaccine and Serum Research Institute, Agricultural Research, Education & Extension Organization, Karaj, Iran for their constant support and guidance.

References

1. Avila-Calderón ED, Lopez-Merino A, Sriranganathan N, Boyle SM, Contreras-Rodríguez A. A history of the development of brucella vaccines. *BioMed Res Int* 2013; 2013:743509.

2. Acharya KP, Kaphle K, Shrestha K, Bastuji BG, Smits HL. Review of brucellosis in Nepal. *Int J Veterinary Sci Med* 2016;4(2):54-62.
3. Basiri H, Akbari N, Azizpour M, Hossein SD, Behrozi-khah AM, Eskandari S. Amplification, cloning and expression of *Brucella melitensis* bp26 gene (OMP28) isolated from Markazi province (Iran) and purification of Bp26 protein. *Archives Razi Institute* 2013;68(2):111-116.
4. Chaudhuri P, Prasad R, Kumar V, Gangaplara A. Recombinant OMP28 antigen-based indirect ELISA for serodiagnosis of bovine brucellosis. *Mol Cell Probes* 2010;24(3):142-145.
5. Gupta VK, Radhakrishnan G, Harms J, Splitter G. Invasive *Escherichia coli* vaccines expressing *Brucella melitensis* outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with *B. melitensis*. *Vaccine* 2012;30(27):4017-4022.
6. Pontes DS, de Azevedo MS, Chatel JM, Langella P, Azevedo V, Miyoshi A. *Lactococcus lactis* as a live vector: heterologous protein production and DNA delivery systems. *Protein Expr Purif* 2011;79(2):165-175.
7. Nouaille S, Ribeiro LA, Miyoshi A, Pontes D, Le Loir Y, Oliveira SC, et al. Heterologous protein production and delivery systems for *Lactococcus lactis*. *Genet Mol Res* 2003;2(1):102-111.
8. Scavone P, Miyoshi A, Rial A, Chabalgoity A, Langella P, Azevedo V, et al. Intranasal immunisation with recombinant *Lactococcus lactis* displaying either anchored or secreted forms of *Proteus mirabilis* MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice. *Microbes Infect* 2007;9(7):821-828.
9. Zhang Q, Zhong J, Huan L. Expression of hepatitis B virus surface antigen determinants in *Lactococcus lactis* for oral vaccination. *Microbiol Res* 2011;166(2):111-120.
10. Azizpour M, Hosseini SD, Jafari P, Akbary N. *Lactococcus lactis*: A new strategy for vaccination. *Avicenna J Med Biotechnol* 2017;9(4):163-168.
11. Carvalho Neta AV, Mol JP, Xavier MN, Paixão TA, Lage AP, Santos RL. Pathogenesis of bovine brucellosis. *Vet J* 2010;184(2):146-155.
12. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. *PLoS Negl Trop Dis* 2012;6(2):e1475.
13. D'Souza R, Pandeya DR, Hong ST. Review: *Lactococcus lactis*: an efficient gram positive cell factory for the production and secretion of recombinant protein. *Biomed Res* 2012;23(1).
14. Bermúdez-Humarán LG. *Lactococcus lactis* as a live vector for mucosal delivery of therapeutic proteins. *Hum Vaccin* 2009;5(4):264-267.
15. Wells JM. Immunomodulatory mechanisms of lactobacilli. *Microb Cell Fact* 2011;10(1):S17.
16. Kumar GB, Ganapathi TR, Bapat VA. Production of hepatitis B surface antigen in recombinant plant systems: an update. *Biotechnol Prog* 2007;23(3):532-539.
17. Chen H. Recent advances in mucosal vaccine development. *J Controlled Release (JCR)* 2000;67(2-3):117-128.
18. Pasquevich KA, Ibañez AE, Coria LM, García Samartino C, Estein SM, Zwerdling A, et al. An oral vaccine based on U-Omp19 induces protection against *B. abortus* mucosal challenge by inducing an adaptive IL-17 immune response in mice. *PLoS One* 2011;6(1):e16203.
19. Sáez D, Fernández P, Rivera A, Andrews E, Oñate A. Oral immunization of mice with recombinant *Lactococcus lactis* expressing Cu, Zn superoxide dismutase of *Brucella abortus* triggers protective immunity. *Vaccine* 2012;30(7):1283-1290.
20. Stabel TJ, Mayfield JE, Tabatabai LB, Wannemuehler MJ. Oral immunization of mice with attenuated *Salmonella typhimurium* containing a recombinant plasmid which codes for production of a 31-kilodalton protein of *Brucella abortus*. *Infect Immun* 1990;58(7):2048-2055.
21. Pontes DS, Dorella FA, Ribeiro LA, Miyoshi A, Le Loir Y, Gruss A, et al. Induction of partial protection in mice after oral administration of *Lactococcus lactis* producing *Brucella abortus* L7/L12 antigen. *J Drug Target* 2003;11(8-10):489-493.
22. Ribeiro LA, Azevedo V, Le Loir Y, Oliveira SC, Dieye Y, Piard JC, et al. Production and targeting of the *Brucella abortus* antigen L7/L12 in *Lactococcus lactis*: a first step towards food-grade live vaccines against brucellosis. *Appl Environ Microbiol* 2002;68(2):910-916.
23. Miyoshi A, Bermúdez-Humarán LG, Ribeiro LA, Le Loir Y, Oliveira SC, Langella P, et al. Heterologous expression of *Brucella abortus* GroEL heat-shock protein in *Lactococcus lactis*. *Microb Cell Fact* 2006;5(1):14.
24. Thavaselvam D, Kumar A, Tiwari S, mMishra M, Prakash A. Cloning and expression of the immunoreactive *Brucella melitensis* 28 kDa outer-membrane protein (Omp28) encoding gene and evaluation of the potential of Omp28 for clinical diagnosis of brucellosis. *J Med Microbiol* 2010;59(4):421-428.